Biosimilar Regulatory Pathway: 351(k) Application Process
The biosimilar regulatory pathway is established by the Biologics Price Competition and Innovation Act (BPCIA) under section 351(k) of the Public Health Service Act. It provides an abbreviated licensure pathway for biological products demonstrated to be biosimilar to an FDA-licensed reference product. FDA describes a stepwise, totality-of-evidence approach in which analytical characterization forms the foundation, with additional animal or clinical work determined by the residual uncertainty in the program.
Key Takeaways
Key Takeaways
- Biosimilars are approved under BPCIA Section 351(k) of the PHS Act, using a stepwise approach with analytical similarity as the foundation
- The totality-of-evidence framework means robust analytical data may reduce the amount of additional clinical evidence needed
- Interchangeability designation requires additional switching study data beyond biosimilarity and enables pharmacy-level substitution
- Indication extrapolation allows approval for reference product indications not directly studied if scientifically justified
- The biosimilar regulatory pathway under BPCIA enables abbreviated approval of biological products that are highly similar to an already-approved reference product with no clinically meaningful differences in safety, purity, or potency. Unlike the generic drug pathway (ANDA) under Section 505(j) of the FD&C Act, the biosimilar pathway does not rely on bioequivalence alone. Instead, it requires a comprehensive demonstration of biosimilarity using analytical, nonclinical, and clinical data evaluated under a totality-of-evidence framework.
- This pathway provides a statutory route for biosimilar competition after the applicable reference-product exclusivity period.
- In this guide, you will learn:
- The BPCIA statutory framework and its provisions
- The stepwise development approach for biosimilars
- Analytical similarity study requirements and expectations
- Clinical pharmacology and comparative clinical study design
- The totality-of-evidence review framework
- Extrapolation of indications
- The patent provisions under BPCIA (the "patent dance")
- ---
BPCIA Biosimilar: Legislative Framework
The Biologics Price Competition and Innovation Act (BPCIA) was enacted as part of the Affordable Care Act (P.L. 111-148) on March 23, 2010. It amended Section 351 of the PHS Act to create a new subsection (k) establishing an abbreviated licensure pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference product.
Key BPCIA Provisions
| Provision | Description | Citation |
|---|---|---|
| Biosimilarity standard | Highly similar with no clinically meaningful differences | 42 U.S.C. 262(i)(2) |
| Interchangeability standard | Biosimilar + can be expected to produce same clinical result in any given patient | 42 U.S.C. 262(k)(4) |
| Reference product exclusivity | 12 years data exclusivity, 4 years filing exclusivity | 42 U.S.C. 262(k)(7) |
| Patent provisions | Information exchange and litigation framework ("patent dance") | 42 U.S.C. 262(l) |
| First interchangeable exclusivity | First interchangeable biosimilar gets 1 year exclusivity | 42 U.S.C. 262(k)(6) |
Exclusivity Timelines
| Event | Timeline from Reference Product First Licensure |
|---|---|
| 351(k) application filing permitted | 4 years |
| 351(k) approval permitted | 12 years |
| Data exclusivity expires | 12 years |
| Orphan drug exclusivity (if applicable) | 7 years (may run concurrently) |
| Pediatric exclusivity (if applicable) | Adds 6 months to existing exclusivity |
The statute provides 12 years of reference-product exclusivity and 4 years before a 351(k) application may be submitted.
Biosimilar Development: The Stepwise Approach
FDA recommends a stepwise development approach for biosimilars, as described in the 2015 guidance "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product."
The Stepwise Development Paradigm
The approach begins with the most sensitive analytical methods and progresses to less sensitive but clinically relevant studies. Each step informs whether the next step is needed and its scope.
| Step | Purpose | Can It Be Waived? |
|---|---|---|
| Step 1: Analytical | Demonstrate structural and functional similarity | No - always required |
| Step 2: Animal | Address residual uncertainty from analytics | Yes - if analytical similarity is robust |
| Step 3: Clinical PK/PD | Demonstrate similar exposure and response | Rarely waived; integral to most programs |
| Step 4: Comparative clinical | Confirm no clinically meaningful differences | May be reduced in scope based on Steps 1-3 |
Pre-IND and BPD Meetings
Before initiating development, biosimilar sponsors should request a Biosimilar Product Development (BPD) meeting with FDA.
| Meeting Type | Purpose | Timing |
|---|---|---|
| BPD Type 1 | Initial assessment of proposed development plan | Before any development |
| BPD Type 2 | Discuss specific development issues (analytics, clinical) | During development |
| BPD Type 3 | General advice on biosimilar development | As needed |
| BPD Type 4 | Pre-BLA meeting equivalent | Before 351(k) submission |
| Pre-IND | Standard pre-IND meeting | Before clinical studies |
Use FDA meetings to align on reference-product strategy, analytical plans, and the scope of any clinical work before the program is locked.
351(k) Application: Analytical Similarity
Analytical characterization is the foundation of every biosimilar development program. FDA's 2015 guidance "Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product" provides the framework.
Categories of Analytical Assessment
| Category | Analyses | Purpose |
|---|---|---|
| Primary structure | Amino acid sequence, peptide mapping, disulfide bonds, free sulfhydryls | Confirm identical primary structure |
| Higher-order structure | CD, FTIR, DSC, HDX-MS, X-ray crystallography | Assess structural similarity |
| Post-translational modifications | Glycan mapping, sialylation, oxidation, deamidation, C-terminal lysine | Compare modification patterns |
| Purity/Impurities | SEC, CE-SDS, cIEF, HCP, residual DNA | Compare impurity profiles |
| Biological activity | Multiple potency assays, receptor binding, cell-based assays | Demonstrate functional similarity |
| Stability | Real-time, accelerated, stressed degradation | Compare degradation profiles |
| General properties | pH, osmolality, appearance, protein concentration | Confirm product attributes |
Statistical Approaches for Analytical Similarity
| Approach | Application | Description |
|---|---|---|
| Equivalence testing | Quantitative attributes with sufficient reference lot data | Demonstrate biosimilar falls within equivalence margins derived from reference variability |
| Quality range | When reference variability is well-characterized | Biosimilar results fall within the quality range of the reference |
| Visual/graphical comparison | Complex data (glycan profiles, spectroscopic data) | Overlay and compare patterns |
| Tier-based approach | Risk-ranked attributes | Tier 1 (most relevant) gets most rigorous statistics; Tier 3 (least relevant) gets raw data comparison |
Reference Product Acquisition
| Requirement | Details |
|---|---|
| Source | Must be the US-licensed reference product for a US 351(k) application |
| Non-US sourced reference | FDA may permit some use of non-US sourced comparator material when bridging data justify the approach |
| Number of lots | Sponsors should use a sufficient number of lots to characterize reference-product variability |
| Expiry considerations | Lot selection should support the intended analytical assessment strategy |
“Key Point: FDA expects the reference-product sampling strategy to be sufficient to characterize lot-to-lot variability for the specific analytical program.
Clinical Requirements for Biosimilar Approval
Clinical Pharmacology Studies
Clinical PK (and PD when appropriate) studies are standard components of biosimilar development programs.
| Study Design Element | Expectation |
|---|---|
| Study type | Comparative, randomized, usually crossover (for PK) or parallel |
| Population | Healthy volunteers (when appropriate) or patients |
| PK endpoints | AUC, Cmax with 80-125% equivalence margins |
| PD endpoints | Clinically relevant PD markers (when validated biomarker exists) |
| Sample size | Powered to support the prespecified PK comparison |
| Reference product | US-licensed reference product (or bridged non-US product) |
When to use healthy volunteers vs. patients:
- Healthy volunteers preferred when the product is safe in healthy populations (e.g., many mAbs at appropriate doses)
- Patients required when safety profile precludes healthy volunteer studies (e.g., oncology mAbs, certain cytokines)
Comparative Clinical Studies
| Study Element | Requirements |
|---|---|
| Design | Randomized, double-blind, parallel-group, active-controlled |
| Primary endpoint | Sensitive clinical endpoint capable of detecting differences (often PD or clinical response rate) |
| Equivalence margins | Pre-specified, clinically justified, and agreed with FDA |
| Population | Sensitive population where differences would be most detectable |
| Indication selection | Most sensitive indication (not necessarily the most common) |
| Duration | Sufficient to assess efficacy, safety, and immunogenicity |
| Immunogenicity | Comparative immunogenicity assessment is mandatory |
Immunogenicity Assessment
Comparative immunogenicity is a critical component of every biosimilar clinical program.
| Assessment Element | Requirement |
|---|---|
| ADA incidence | Head-to-head comparison of ADA rates |
| ADA titers | Compare distribution of titers |
| Neutralizing antibodies | Compare NAb rates and titers |
| Clinical impact | Assess impact on PK, efficacy, and safety |
| Time course | Multiple sampling points through study duration |
| Assay | Use same validated assay for both biosimilar and reference product |
Select the most sensitive clinical indication and the most homogeneous patient population for your comparative clinical study. FDA expects the study to be designed to detect clinically meaningful differences if they exist. Using a less sensitive population or endpoint may result in FDA requesting additional studies. Discuss indication and endpoint selection at the BPD Type 2 meeting.
Biosimilar FDA Approval: Totality of Evidence and Extrapolation
Totality of Evidence Framework
FDA evaluates the 351(k) application using a totality-of-evidence approach, weighing all data from the stepwise development program.
| Evidence Component | Weight in Assessment |
|---|---|
| Analytical similarity | Highest - foundation of assessment |
| Functional assays | High - confirms biological similarity |
| Animal data | Moderate - supportive |
| Clinical PK/PD | High - confirms human PK similarity |
| Comparative clinical | High - confirms clinical similarity |
| Immunogenicity | Critical - can differentiate otherwise similar products |
The key principle is that the overall data package should be tailored to the residual uncertainty remaining after analytical and functional assessment. In some programs, robust analytical similarity may reduce the amount of additional clinical evidence needed.
Extrapolation of Indications
One of the most significant features of the 351(k) pathway is the ability to extrapolate approval to indications of the reference product that were not directly studied in the biosimilar clinical program.
| Extrapolation Requirement | Details |
|---|---|
| Scientific justification | Must demonstrate that similarity in one indication supports similarity in others |
| Mechanism of action | Must be the same across extrapolated indications |
| Target/receptor | Must be the same or relevant |
| Pharmacology | PK/PD relationship must be applicable |
| Immunogenicity | Must not differ in ways that would affect other indications |
| Safety profile | Must be applicable across indications |
Example: A biosimilar to adalimumab studied in rheumatoid arthritis may be approved for all adalimumab indications (Crohn's disease, psoriasis, uveitis, etc.) based on extrapolation, provided the mechanism of action (TNF-alpha inhibition) is the same across indications and there are no indication-specific safety concerns.
“Key Point: FDA may permit extrapolation to indications not directly studied when the scientific justification supports doing so.
Patent Provisions: The BPCIA Patent Dance
BPCIA established a structured process for patent dispute resolution between biosimilar applicants and reference product sponsors, commonly called the "patent dance."
Patent Dance Steps
| Step | Timeline | Action |
|---|---|---|
| Step 1 | Within 20 days of 351(k) acceptance | Applicant provides copy of application and manufacturing information to reference product sponsor (RPS) |
| Step 2 | Within 60 days of Step 1 | RPS provides list of relevant patents and identification of patents for immediate litigation |
| Step 3 | Within 60 days of Step 2 | Applicant responds with claims of invalidity, unenforceability, or non-infringement for each patent; identifies patents for immediate litigation |
| Step 4 | Within 15 days of Step 3 | Parties negotiate which patents to litigate first (Phase 1 litigation) |
| Step 5 | Within 30 days of Step 4 | RPS files patent infringement suit on negotiated patents |
| Step 6 | 180 days before commercial launch | Applicant provides notice of commercial marketing |
| Step 7 | After notice | RPS may seek preliminary injunction; remaining patents litigated (Phase 2) |
Consequences of Not Participating
The patent dance provisions are technically optional for the biosimilar applicant, but opting out has consequences:
- If the applicant does not provide its application within 20 days, the RPS may bring an immediate action for patent infringement under 42 U.S.C. 262(l)(9)(C)
- The RPS may seek a preliminary injunction
- The Supreme Court ruled in Sandoz v. Amgen (2017) that the 180-day notice of commercial marketing may be provided before FDA approval, but the applicant may face state law claims for doing so
FDA Purple Book and Biosimilar Product Information
The FDA Purple Book (Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations) is the official resource for biosimilar information.
Purple Book Content
| Information | Description |
|---|---|
| Reference product listing | All licensed biological products under Section 351(a) |
| Biosimilar products | Products determined to be biosimilar to a reference product |
| Interchangeable products | Products determined to be interchangeable |
| Exclusivity dates | Reference product exclusivity expiration |
| BLA number | Application number for each product |
| Licensure date | Date of first approval |
The Purple Book is available online at purplebooksearch.fda.gov and is updated regularly.
Development time varies substantially by product complexity, comparator strategy, analytical program, and the amount of clinical work needed to address residual uncertainty.
Key Regulatory References
| Reference | Citation |
|---|---|
| BPCIA Legislation | P.L. 111-148, Section 7002 (2010) |
| PHS Act Section 351(k) | 42 U.S.C. 262(k) |
| Scientific Considerations in Demonstrating Biosimilarity | FDA Guidance (2015) |
| Quality Considerations in Demonstrating Biosimilarity | FDA Guidance (2015) |
| Clinical Pharmacology Data to Support Biosimilarity | FDA Guidance (2014) |
| Biosimilar Product Labeling | FDA Guidance (2018) |
| Reference Product Exclusivity | FDA Guidance (2014) |
| Nonproprietary Naming of Biological Products | FDA Guidance (2017) |
| Interchangeability Considerations | FDA Guidance (2019) |
| Formal Meetings Between FDA and Sponsors (BPD Meetings) | FDA Guidance (2015) |
| ICH Q5E | Comparability of Biotechnological Products |
| Sandoz v. Amgen | 581 U.S. 28 (2017) |
| FDA Purple Book | purplebooksearch.fda.gov |